Research-for-Cure Academy

Yeukai Musodza

Nationality: Zimbabwean
Institution: University of Zimbabwe College of Health Sciences Clinical Trials Centre
Country of work: Zimbabwe

What is your motivation for engaging in HIV cure and remission research?

I am a medical doctor engaged in HIV care and treatment in Zimbabwe, a high HIV-burden, resource limited country. Whilst ART has dramatically improved the prognosis of HIV infected individuals, it only suppresses the virus without eradicating it. It also requires lifelong adherence which is a challenge among youths and adolescents. ART also carries a risk of toxicities which require monitoring which strains already limited resources. It is imperative that the HIV cure agenda be advanced to achieve the goal of ending HIV/AIDS.

What is your current area of research?

I am a research medical officer at University of Zimbabwe College of Health Sciences Clinical Trials Centre. I am involved in multiple HIV treatment and HIV prevention studies under the ACTG and HPTN. One of the studies is A5354 study, which seeks to characterize the establishment of HIV-1 reservoir and HIV-1-specific immunity after early ART initiation in acutely infected patients. Another is HPTN 081 study which seeks to evaluate the efficacy of broadly neutralizing the monoclonal antibody, VRCO1, for HIV prevention in women at high risk of acquiring HIV.